BioCryst Pharmaceuticals, Inc.
Financials
Valuation Metrics
BioCryst Pharmaceuticals, Inc.'s Market Cap is $2.10B. At end of 2025 it was $1.65B. Ranked #1982 of 3,114 in US market (top 64%), #745 of 1,469 on NASDAQ (top 51%), #133 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 50%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.10B | US#1,982/3,114 Sec#133/265 |
| Revenue | $941M | US#1,896/3,114 Sec#55/265 |
| Net Income | $-385M | US—/3,114 Sec—/265 |
| Total Assets | $558M | US#2,723/3,114 Sec#151/265 |
| Net Assets | $-454M | US#3,009/3,114 Sec#262/265 |
| Employees | 435 | US#2,306/3,114 Sec#85/265 |
| Value | ||
| P/S | 2.23x | US#1,327/3,114 Sec#31/265 |
| FCF Yield | 17.03% | US#206/3,114 Sec#7/265 |
| Profitability | ||
| ROA | -68.96% | US#3,028/3,114 Sec#239/265 |
| Op. Margin | -33.29% | US#2,621/3,114 Sec#105/265 |
| Revenue Growth | 68.72% | US#154/3,114 Sec#40/265 |
| Financial Health | ||
| Total Debt | $410M | US#1,975/3,114 Sec#70/265 |
| FCF | $357M | US#1,059/3,114 Sec#38/265 |
| Cash | $155M | US#1,937/3,114 Sec#133/265 |
| Current Ratio | 2.32x | US#1,072/3,114 Sec#210/265 |
| Performance | ||
| 1Y Return | 12.70% | US#1,448/3,114 Sec#132/265 |
| 1M Return | 0.98% | US#2,382/3,114 Sec#151/265 |
| From 52W High | -26.47% | US#1,976/3,114 Sec#124/265 |
| 1Y MDD | -31.14% | US#1,319/3,114 Sec#67/265 |
| Trading | ||
| Volume | 2,339,668 shares | US#534/3,114 Sec#36/265 |
| Trading Value | $19M | US#1,675/3,114 Sec#123/265 |
| Per Share | ||
| EPS | $-1.51 | US—/3,114 Sec—/265 |
| BPS | $-1.79 | US—/3,114 Sec—/265 |
Company Info
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.